Dr. Singer is Professor of Medicine at Harvard Medical School and Professor in the Department of Epidemiology at Harvard TH Chan School of Public Health and based in the Division of General Internal Medicine at Massachusetts General Hospital in Boston, Massachusetts.

Dr. Singer’s research focuses on preventing stroke in individuals with atrial fibrillation (AF). He led the design and analysis of the Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF), which established that well-controlled warfarin anticoagulation can safely reverse stroke risk in patients with AF. With Dr. Alan Go at Kaiser Permanente, California, their ATRIA cohort studies established that the randomized trials of anticoagulants in AF were well replicated in usual clinical care. He served on the Executive Committee of the ROCKET-AF trial that established that rivaroxaban was non-inferior to warfarin in preventing stroke in AF. He has published multiple papers on risk factors for stroke and for bleeding in patients with AF. Through empirical work and decision modeling, he has emphasized the concept of expected net clinical benefit in making the anticoagulation decision in AF.  Much of his recent work has focused on the relationship between AF “burden” and stroke risk, the temporal relationship between paroxysmal AF and stroke risk, and screening for AF – in particular, the GUARD-AF and VITAL-AF randomized trials. Dr. Singer was Chair of the 2004 and 2008 American College of Chest Physicians Guidelines on Antithrombotic Therapy for AF. Dr. Singer’s work has been recognized by multiple awards, invited lectures, and editorials.